Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $25 | $40 | $45 | $27 |
| Short-Term Investments | $89 | $79 | $172 | $164 |
| Receivables | $0 | $0 | $0 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $12 | $9 | $13 | $13 |
| Total Curr. Assets | $126 | $129 | $232 | $205 |
| Property Plant & Equip (Net) | $1 | $2 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $7 | $7 |
| Long-Term Investments | $90 | $63 | $12 | $34 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $4 | $3 | $4 |
| Total NC Assets | $94 | $69 | $23 | $46 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $220 | $197 | $255 | $251 |
| Liabilities | – | – | – | – |
| Payables | $5 | $9 | $10 | $10 |
| Short-Term Debt | $0 | $0 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $4 | $0 | $0 | $0 |
| Other Curr. Liab. | $23 | $22 | $11 | $12 |
| Total Curr. Liab. | $32 | $31 | $22 | $23 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $20 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $13 | $9 | $35 | $31 |
| Total NC Liab. | $33 | $9 | $35 | $31 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $1 | $1 |
| Total Liabilities | $65 | $40 | $57 | $54 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$903 | -$771 | -$682 | -$595 |
| AOCI | $0 | -$0 | -$1 | -$0 |
| Other Equity | $1,058 | $928 | $881 | $793 |
| Total Equity | $156 | $157 | $198 | $197 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $220 | $197 | $255 | $251 |
| Net Debt | -$25 | -$39 | -$45 | -$27 |